Kura Q3: KOMZIFTI Revenue Up 53% to $13.9M; Darlifarnib FDA Alignment
KURA is trading near its 52-week low of $6.75 (10% above the low).
Summary
Kura's KOMZIFTI sales grew 53% sequentially to $13.9 million in Q3 2026, and the company secured FDA alignment on a ~40-patient registrational study of darlifarnib in HRAS-mutant salivary gland cancer. With $492.1 million in cash and up to $300 million of Oberland Capital capacity, management says funding extends beyond the 2028 KOMET-017 topline.
Key Events · Earnings and Guidance · KURA
-
KOMZIFTI Revenue Grows 53% Sequentially
Q3 2026 net product revenue was $13.9 million versus $9.1 million in Q2 2026, with roughly 150 new patient starts (up 30%) and more than 420 total prescriptions (up 65%).
-
Darlifarnib Registrational Path Aligned With FDA
FDA alignment reached on a single-arm monotherapy registrational study of about 40 HRAS-mutant salivary gland cancer patients, with initiation targeted for 1H 2027.
-
Cash Funds Operations Past 2028 Readout
$492.1 million in cash, cash equivalents and short-term investments at September 30, 2026, plus $180 million in anticipated Kyowa Kirin milestone payments and up to $300 million of conditional Oberland Capital capacity, is expected to fund operations beyond KOMET-017 topline in 2028.
-
Q3 Net Loss $70.2 Million
R&D was $66.9 million and SG&A $30.2 million, producing a $70.2 million net loss versus $74.1 million a year earlier; 2026 collaboration revenue guidance was updated to $40-45 million.
Analysis · KURA · Life Sciences
KOMZIFTI's second full quarter of sales reached $13.9 million, up 53% from $9.1 million in Q2, while new patient starts rose 30% and total prescriptions climbed 65% — evidence the launch is compounding rather than plateauing, and Kura still holds a majority of new patient starts in the R/R NPM1-mutant AML menin inhibitor class. Separately, the company reached FDA alignment on a roughly 40-patient single-arm registrational study of darlifarnib in HRAS-mutant salivary gland cancer, a potential second approval with study start targeted for the first half of 2027. Cash of $492.1 million, plus $180 million in anticipated Kyowa Kirin milestone payments and up to $300 million of conditional Oberland Capital capacity, is expected to fund operations beyond the KOMET-017 frontline topline readout in 2028 — so the equity does not need to be sold to reach that catalyst. The offset is cost: the Q3 net loss was $70.2 million and 2026 collaboration revenue guidance was trimmed to $40-45 million, reflecting accounting recognition rather than cash timing.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KURA was trading at $7.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $673.4M. The 52-week trading range was $6.75 to $13.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.